| Field | Specification |
|---|---|
| Target | |
| Alternative names | Basic-helix-loop-helix-PAS protein MOP3; Brain and muscle ARNT-like 1; Class E basic helix-loop-helix protein 5; bHLHe5; Member of PAS protein 3; PAS domain-containing protein 3; bHLH-PAS protein JAP3; ARNTL; BHLHE5, BMAL1, MOP3, PASD3 |
| UniProt # | |
| Host | |
| Clonality | |
| Isotype | |
| Reactivity | |
| Applications | |
| Immunogen | E.coli-derived human BMAL1/ARNTL recombinant protein (Position: R116-E447). |
| Molecular weight | |
| Purification | |
| Reconstitution | |
| Cellular localization | |
| Concentration | |
| Form | Lyophilized |
| Storage | |
| Catalog no. (Mfr.) | |
| Main SKU |
Product Overview
This rabbit polyclonal antibody recognizes basic helix-loop-helix ARNT-like protein 1 (gene BMAL1) in human, mouse and rat samples and is validated for Western blot, IHC, ICC/IF and ELISA. The predicted molecular weight is 68.8 kDa, and the supplier reports an observed band at about 75 kDa.
BMAL1 (also called ARNTL) is a bHLH-PAS transcription factor that forms a heterodimer with CLOCK or NPAS2 to activate E-box genes such as PER and CRY, which in turn repress BMAL1–CLOCK activity. This feedback loop is the core of the mammalian circadian clock, and BMAL1 is essential for circadian rhythms of behavior and metabolism.
| Target | Basic helix-loop-helix ARNT-like protein 1 (gene BMAL1; UniProt O00327, human) |
|---|---|
| Host / Clonality / Isotype | Rabbit / Polyclonal / Rabbit IgG |
| Reactivity | Human, Mouse, Rat |
| Form | Lyophilized |
| Formulation | Per vial: 4 mg trehalose; 0.9 mg NaCl; 0.2 mg Na2HPO4 |
| Calculated MW | 68.8 kDa |
| Observed MW | 75 kDa |
| Storage | As supplied: −20 °C for up to 12 months from receipt. After reconstitution: 4 °C for up to 1 month, or aliquot and keep at −20 °C for up to 6 months. Avoid repeated freeze–thaw cycles. |
Validated Applications
| Western blot | 0.25–0.5 µg/mL (Human, Mouse, Rat) |
|---|---|
| IHC (paraffin sections) | 2–5 µg/mL (Human, Mouse, Rat) |
| Immunocytochemistry / Immunofluorescence | 5 µg/mL (Human) |
| ELISA | 0.1–0.5 µg/mL |
Samples with a confirmed band (WB): human U2OS cells, human A549 cells, rat brain tissue, rat liver tissue, mouse brain tissue, mouse liver tissue.
Recommended loading (WB): 20–40 µg of total protein per lane.
Conditions in the example images (WB): 10% SDS-PAGE under reducing conditions, 30 µg lysate per lane, transfer to nitrocellulose membrane, blocking in 5% non-fat milk, primary antibody at 0.5 µg/mL overnight at 4 °C, HRP-conjugated secondary antibody at 1:5000, ECL detection.
Samples with confirmed staining (IHC): human brain tissue, mouse brain tissue, rat brain tissue.
Recommended antigen retrieval: heat-mediated, in TE buffer (pH 9.0); citrate buffer (pH 6.0) can be used instead.
Conditions in the example images (IHC): heat-mediated antigen retrieval in EDTA buffer (pH 8.0).
Samples with confirmed staining (ICC/IF): U2OS cells.
Immunogen
Recombinant human BMAL1/ARNTL fragment (Arg116–Glu447), expressed in E. coli.
Reactivity Notes
The supplier lists reactivity with human, mouse and rat. UniProt places basic helix-loop-helix ARNT-like protein 1 in the nucleus and cytoplasm. Tissue expression noted by UniProt (human): Hair follicles (at protein level). The samples tested by the supplier (listed above) are a practical starting point for positive controls.
Safety
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
